You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Wearable Fluorescence Imaging Device for IntraoperativeIdentification of Brain Tumors

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 102

    ABSTRACT Approximately 700,000 people in the United States are diagnosed with a primary brain tumor. Of these, malignant gliomas (MGs) account for approximately 40% of all intracranial tumors, with an overall survival rate of only ~34%. Surgical resection remains the cornerstone of therapy and the extent of resection correlates with survival. Fluorescence imaging has emerged as an adjunctive techn ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Time-resolved laser speckle contrast imaging of resting-state functional connectivity in neonatal brain

    SBC: BIOPTICS TECHNOLOGY LLC            Topic: 103

    ABSTRACT Continuous monitoring of neonatal brain development is crucial for effective management of brain injury and associated complications, thus reducing healthcare burden and costs. One rapidly developing method for early characterization of abnormal brain development is to map resting-state functional connectivity (rs-FC) across distinct regions of the brain. However, currently available neur ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Noninvasive sleep enhancement and behavior monitoring technologies for Alzheimer's model mice

    SBC: SIGNAL SOLUTIONS LLC            Topic: NIA

    The aims of this project are to develop new technologies to identify and track sleep and wake abnormalities present in mouse models of Alzheimer’s disease (AD), as well as to test a sleep enhancement technology for applications in AD animal research. Signal Solutions, LLC, has previously developed and commercialized a piezoelectric based system for noninvasive, high-throughput sleep and wake mon ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. I-RED Southeast XLerator Network

    SBC: XLERATEHEALTH, LLC            Topic: 500

    Project Summary I-RED Southeast XLerator Network, powered by XLerateHealth, LLC in collaboration with the University of Kentucky as the lead academic partner institution, proposes to develop a suite of experience-based entrepreneurship education products and commercialization education tools to address the needs of academic institutions and their faculty, researchers, innovators, and graduate/unde ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Improved Diagnosis of Shunt Malfunction with Automatic Quantification of Ventricular Space

    SBC: CARINA MEDICAL LLC            Topic: NINDS

    ABSTRACT Hydrocephalus is the buildup of cerebrospinal fluid (CSF) in the cavities (ventricles) deep within the brain. The most common treatment for hydrocephalus is CSF diversion via ventriculoperitoneal (VP) shunting. Over 30,000 VP shunts are placed per year in the United States by some estimates. Despite how commonly this surgery is performed, the complication rate has been estimated at almost ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Algorithm to Identify Patients at Risk of Medication-Related Hospitalization

    SBC: L. KRENK, INC.            Topic: R

    The long-range goal of this fast-track research application is to improve healthcare quality and reduce healthcare costs nationwide among those at risk for medication-related hospitalization. The specific objective of this proposed research is to develop an algorithm that uses existing electronic health information to efficiently identify patients at risk of medication-related hospitalization so t ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. I-RED Southeast XLerator Network: Business Fundamentals for Core Facility Directors

    SBC: XLERATEHEALTH, LLC            Topic: NIGMS

    Project Summary Biomedical research is increasingly reliant on sophisticated technology that requires advanced technical skills. This shift in structure of academic research environments demands sufficient resources to perpetuate cutting edge research programs. Therefore, there is an increasing need for highly functional institutionally-based cores providing services with a rate structure that fac ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Using siRNAs against tau circular RNAs as a rational therapy for Alzheimer's disease

    SBC: CircCure Corporation            Topic: R

    Summary:The formation of neurofibrillary tangles (NFT) formed by aggregation of the microtubule-associated protein tau (MAPT) is a hallmark of Alzheimer’s disease (AD) and the likely cause of neuronal death. Currently, there are no rational treatments available that directly target NFT formation and thus address the direct molecular cause for AD. Based on our academic research, we will develop a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Engineered Exosomes for Targeted Delivery of the CRISPR/Cas9 Genome-editor

    SBC: 3P BIOTECHNOLOGIES, INC.            Topic: OD

    Technical AbstractGenetic mutations have been identified as a causative factor in numerous diseases. The genome editing system CRISPR/Cas9 is a recent development in gene therapy. Both viral and non-viral vectors have been used in attempts to direct delivery of Cas9 to specific locations with advantages and limitations similar to those known for other nucleic acid-based therapeutics. These challen ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government